Sakar Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.3 pts more than Nifty Microcap 250 and 9.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sakar Healthcare reported strong full-year performance with standalone revenue from operations growing 42% to Rs 25,174 lakh from Rs 17,758 lakh in the prior year. Profit after tax surged 74% to Rs 3,048 lakh from Rs 1,750 lakh, driven by higher volumes and operational efficiency. EPS improved from Rs 7.97 to Rs 13.70. The company also appointed new secretarial auditors (Kashyap R. Mehta & Partners) to fill a casual vacancy after the resignation of Nishant Pandya & Associates. Statutory auditors issued an unmodified opinion, and the company clarified that consolidated and standalone results are identical as its subsidiary (Sakar Oncology Private Limited) had no business transactions during the year.
Strong double-digit growth in both revenue and profit positions the company favourably for shareholders. The 74% PAT growth well exceeds the 25% threshold, indicating robust operational performance. Working capital consumption (inventory up 61%, receivables up 63%) warrants monitoring for cash flow implications despite positive operating cash flow of Rs 4,926 lakh.